It was estimated that around 20 percent of those with underlying health conditions who had COVID-19 in the United States from January 22 to May 30, 2020 died from the disease, compared to just 2 percent of COVID-patients without underlying health conditions. Underlying health conditions such as cardiovascular disease, chronic lung disease, or diabetes greatly increase the chance of death due to COVID-19. This statistic shows the percentage of people in the U.S. who had COVID-19 from January 22 to May 30, 2020 with and without underlying health conditions who died, by age.

For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

As of April 26, 2023, the number of both confirmed and presumptive positive cases of the COVID-19 disease reported in the United States had reached over 104 million with over 1.1 million deaths reported among these cases.

Coronavirus deaths by age in the U.S. Daily new cases of COVID-19 hit record highs in the United States at the beginning of 2022. Underlying health conditions can worsen cases of coronavirus, and case fatality rates among confirmed COVID-19 patients increase with age. The highest number of deaths from COVID-19 have been among those aged 85 years and older, with this age group accounting for over 300 thousand deaths.

Where has this coronavirus come from? Coronaviruses are a large group of viruses transmitted between animals and people that cause illnesses ranging from the common cold to more severe diseases. The novel coronavirus that is currently infecting humans was already circulating among certain animal species. The first human case of this new coronavirus strain was reported in China at the end of December 2019. The coronavirus was named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and its associated disease is known as COVID-19.

Context

Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus. Most people infected with COVID-19 virus will experience mild to moderate respiratory illness and recover without requiring special treatment. Older people, and those with underlying medical problems like cardiovascular disease, diabetes, chronic respiratory disease, and cancer are more likely to develop serious illness. During the entire course of the pandemic, one of the main problems that healthcare providers have faced is the shortage of medical resources and a proper plan to efficiently distribute them. In these tough times, being able to predict what kind of resource an individual might require at the time of being tested positive or even before that will be of immense help to the authorities as they would be able to procure and arrange for the resources necessary to save the life of that patient.

The main goal of this project is to build a machine learning model that, given a Covid-19 patient's current symptom, status, and medical history, will predict whether the patient is in high risk or not.

content

The dataset was provided by the Mexican government (link). This dataset contains an enormous number of anonymized patient-related information including pre-conditions. The raw dataset consists of 21 unique features and 1,048,576 unique patients. In the Boolean features, 1 means "yes" and 2 means "no". values as 97 and 99 are missing data.

• sex: 1 for female and 2 for male.
• age: of the patient.
• classification: covid test findings. Values 1-3 mean that the patient was diagnosed with covid in different degrees. 4 or higher means that the patient is not a carrier of covid or that the test is inconclusive.
• patient type: type of care the patient received in the unit. 1 for returned home and 2 for hospitalization.
• pneumonia: whether the patient already have air sacs inflammation or not.
• pregnancy: whether the patient is pregnant or not.
• diabetes: whether the patient has diabetes or not.
• copd: Indicates whether the patient has Chronic obstructive pulmonary disease or not.
• asthma: whether the patient has asthma or not.
• inmsupr: whether the patient is immunosuppressed or not.
• hypertension: whether the patient has hypertension or not.
• cardiovascular: whether the patient has heart or blood vessels related disease.
• renal chronic: whether the patient has chronic renal disease or not.
• other disease: whether the patient has other disease or not.
• obesity: whether the patient is obese or not.
• tobacco: whether the patient is a tobacco user.
• usmr: Indicates whether the patient treated medical units of the first, second or third level.
• medical unit: type of institution of the National Health System that provided the care.
• intubed: whether the patient was connected to the ventilator.
• icu: Indicates whether the patient had been admitted to an Intensive Care Unit.
• date died: If the patient died indicate the date of death, and 9999-99-99 otherwise.

Note: Reporting of new COVID-19 Case Surveillance data will be discontinued July 1, 2024, to align with the process of removing SARS-CoV-2 infections (COVID-19 cases) from the list of nationally notifiable diseases. Although these data will continue to be publicly available, the dataset will no longer be updated.

Authorizations to collect certain public health data expired at the end of the U.S. public health emergency declaration on May 11, 2023. The following jurisdictions discontinued COVID-19 case notifications to CDC: Iowa (11/8/21), Kansas (5/12/23), Kentucky (1/1/24), Louisiana (10/31/23), New Hampshire (5/23/23), and Oklahoma (5/2/23). Please note that these jurisdictions will not routinely send new case data after the dates indicated. As of 7/13/23, case notifications from Oregon will only include pediatric cases resulting in death.

This case surveillance public use dataset has 12 elements for all COVID-19 cases shared with CDC and includes demographics, any exposure history, disease severity indicators and outcomes, presence of any underlying medical conditions and risk behaviors, and no geographic data.

CDC has three COVID-19 case surveillance datasets:

• COVID-19 Case Surveillance Public Use Data with Geography: Public use, patient-level dataset with clinical data (including symptoms), demographics, and county and state of residence. (19 data elements)
• COVID-19 Case Surveillance Public Use Data: Public use, patient-level dataset with clinical and symptom data and demographics, with no geographic data. (12 data elements)
• COVID-19 Case Surveillance Restricted Access Detailed Data: Restricted access, patient-level dataset with clinical and symptom data, demographics, and state and county of residence. Access requires a registration process and a data use agreement. (33 data elements)

• Data elements can be found on the COVID-19 case report form located at www.cdc.gov/coronavirus/2019-ncov/downloads/pui-form.pdf.
• Data are considered provisional by CDC and are subject to change until the data are reconciled and verified with the state and territorial data providers.
• Some data cells are suppressed to protect individual privacy.
• The datasets will include all cases with the earliest date available in each record (date received by CDC or date related to illness/specimen collection) at least 14 days prior to the creation of the current datasets. This 14-day lag allows case reporting to be stabilized and ensures that time-dependent outcome data are accurately captured.
• Datasets are updated monthly.
• Datasets are created using CDC’s Policy on Public Health Research and Nonresearch Data Management and Access and include protections designed to protect individual privacy.
• For more information about data collection and reporting, please see https://www.cdc.gov/coronavirus/2019-ncov/covid-data/about-us-cases-deaths.html.
• For more information about the COVID-19 case surveillance data, please see https://www.cdc.gov/coronavirus/2019-ncov/covid-data/faq-surveillance.html
  

Overview

The COVID-19 case surveillance database includes individual-level data reported to U.S. states and autonomous reporting entities, including New York City and the District of Columbia (D.C.), as well as U.S. territories and affiliates. On April 5, 2020, COVID-19 was added to the Nationally Notifiable Condition List and classified as “immediately notifiable, urgent (within 24 hours)” by a Council of State and Territorial Epidemiologists (CSTE) Interim Position Statement (Interim-20-ID-01). CSTE updated the position statement on August 5, 2020, to clarify the interpretation of antigen detection tests and serologic test results within the case classification (Interim-20-ID-02). The statement also recommended that all states and territories enact laws to make COVID-19 reportable in their jurisdiction, and that jurisdictions conducting surveillance should submit case notifications to CDC. COVID-19 case surveillance data are collected by jurisdictions and reported voluntarily to CDC.

For more information: NNDSS Supports the COVID-19 Response | CDC.

The deidentified data in the “COVID-19 Case Surveillance Public Use Data” include demographic characteristics, any exposure history, disease severity indicators and outcomes, clinical data, laboratory diagnostic test results, and presence of any underlying medical conditions and risk behaviors. All data elements can be found on the COVID-19 case report form located at www.cdc.gov/coronavirus/2019-ncov/downloads/pui-form.pdf.

COVID-19 Case Reports

COVID-19 case reports have been routinely submitted using nationally standardized case reporting forms. On April 5, 2020, CSTE released an Interim Position Statement with national surveillance case definitions for COVID-19 included. Current versions of these case definitions are available here: https://ndc.services.cdc.gov/case-definitions/coronavirus-disease-2019-2021/.

All cases reported on or after were requested to be shared by public health departments to CDC using the standardized case definitions for laboratory-confirmed or probable cases. On May 5, 2020, the standardized case reporting form was revised. Case reporting using this new form is ongoing among U.S. states and territories.

Data are Considered Provisional

• The COVID-19 case surveillance data are dynamic; case reports can be modified at any time by the jurisdictions sharing COVID-19 data with CDC. CDC may update prior cases shared with CDC based on any updated information from jurisdictions. For instance, as new information is gathered about previously reported cases, health departments provide updated data to CDC. As more information and data become available, analyses might find changes in surveillance data and trends during a previously reported time window. Data may also be shared late with CDC due to the volume of COVID-19 cases.
• Annual finalized data: To create the final NNDSS data used in the annual tables, CDC works carefully with the reporting jurisdictions to reconcile the data received during the year until each state or territorial epidemiologist confirms that the data from their area are correct.
• Access Addressing Gaps in Public Health Reporting of Race and Ethnicity for COVID-19, a report from the Council of State and Territorial Epidemiologists, to better understand the challenges in completing race and ethnicity data for COVID-19 and recommendations for improvement.

Data Limitations

To learn more about the limitations in using case surveillance data, visit FAQ: COVID-19 Data and Surveillance.

Data Quality Assurance Procedures

CDC’s Case Surveillance Section routinely performs data quality assurance procedures (i.e., ongoing corrections and logic checks to address data errors). To date, the following data cleaning steps have been implemented:

• Questions that have been left unanswered (blank) on the case report form are reclassified to a Missing value, if applicable to the question. For example, in the question “Was the individual hospitalized?” where the possible answer choices include “Yes,” “No,” or “Unknown,” the blank value is recoded to Missing because the case report form did not include a response to the question.
• Logic checks are performed for date data. If an illogical date has been provided, CDC reviews the data with the reporting jurisdiction. For example, if a symptom onset date in the future is reported to CDC, this value is set to null until the reporting jurisdiction updates the date appropriately.
• Additional data quality processing to recode free text data is ongoing. Data on symptoms, race and ethnicity, and healthcare worker status have been prioritized.

Data Suppression

To prevent release of data that could be used to identify people, data cells are suppressed for low frequency (<5) records and indirect identifiers (e.g., date of first positive specimen). Suppression includes rare combinations of demographic characteristics (sex, age group, race/ethnicity). Suppressed values are re-coded to the NA answer option; records with data suppression are never removed.

For questions, please contact Ask SRRG (eocevent394@cdc.gov).

Additional COVID-19 Data

COVID-19 data are available to the public as summary or aggregate count files, including total counts of cases and deaths by state and by county. These

Pre-existing conditions of people who died due to COVID-19, broken down by country, broad age group, and place of death occurrence, usual residents of England and Wales.

A. SUMMARY This archived dataset includes data for population characteristics that are no longer being reported publicly. The date on which each population characteristic type was archived can be found in the field “data_loaded_at”. B. HOW THE DATASET IS CREATED Data on the population characteristics of COVID-19 cases are from:  * Case interviews  * Laboratories  * Medical providers    These multiple streams of data are merged, deduplicated, and undergo data verification processes.   Race/ethnicity * We include all race/ethnicity categories that are collected for COVID-19 cases. * The population estimates for the "Other" or “Multi-racial” groups should be considered with caution. The Census definition is likely not exactly aligned with how the City collects this data. For that reason, we do not recommend calculating population rates for these groups. Gender * The City collects information on gender identity using these guidelines. Skilled Nursing Facility (SNF) occupancy * A Skilled Nursing Facility (SNF) is a type of long-term care facility that provides care to individuals, generally in their 60s and older, who need functional assistance in their daily lives.  * This dataset includes data for COVID-19 cases reported in Skilled Nursing Facilities (SNFs) through 12/31/2022, archived on 1/5/2023. These data were identified where “Characteristic_Type” = ‘Skilled Nursing Facility Occupancy’. Sexual orientation * The City began asking adults 18 years old or older for their sexual orientation identification during case interviews as of April 28, 2020. Sexual orientation data prior to this date is unavailable. * The City doesn’t collect or report information about sexual orientation for persons under 12 years of age. * Case investigation interviews transitioned to the California Department of Public Health, Virtual Assistant information gathering beginning December 2021. The Virtual Assistant is only sent to adults who are 18+ years old. Learn more about our data collection guidelines pertaining to sexual orientation. Comorbidities * Underlying conditions are reported when a person has one or more underlying health conditions at the time of diagnosis or death. Homelessness Persons are identified as homeless based on several data sources: * self-reported living situation * the location at the time of testing * Department of Public Health homelessness and health databases * Residents in Single-Room Occupancy hotels are not included in these figures. These methods serve as an estimate of persons experiencing homelessness. They may not meet other homelessness definitions. Single Room Occupancy (SRO) tenancy * SRO buildings are defined by the San Francisco Housing Code as having six or more "residential guest rooms" which may be attached to shared bathrooms, kitchens, and living spaces. * The details of a person's living arrangements are verified during case interviews. Transmission Type * Information on transmission of COVID-19 is based on case interviews with individuals who have a confirmed positive test. Individuals are asked if they have been in close contact with a known COVID-19 case. If they answer yes, transmission category is recorded as contact with a known case. If they report no contact with a known case, transmission category is recorded as community transmission. If the case is not interviewed or was not asked the question, they are counted as unknown. C. UPDATE PROCESS This dataset has been archived and will no longer update as of 9/11/2023. D. HOW TO USE THIS DATASET Population estimates are only available for age groups and race/ethnicity categories. San Francisco po

Among COVID-19 patients in the United States from February 12 to March 16, 2020, estimated case-fatality rates were highest for adults aged 85 years and older. Younger people appeared to have milder symptoms, and there were no deaths reported among persons aged 19 years and under.

Tracking the virus in the United States The outbreak of a previously unknown viral pneumonia was first reported in China toward the end of December 2019. The first U.S. case of COVID-19 was recorded in mid-January 2020, confirmed in a patient who had returned to the United States from China. The virus quickly started to spread, and the first community-acquired case was confirmed one month later in California. Overall, there had been approximately 4.5 million coronavirus cases in the country by the start of August 2020.

U.S. health care system stretched California, Florida, and Texas are among the states with the most coronavirus cases. Even the best-resourced hospitals in the United States have struggled to cope with the crisis, and certain areas of the country were dealt further blows by new waves of infections in July 2020. Attention is rightly focused on fighting the pandemic, but as health workers are redirected to care for COVID-19 patients, the United States must not lose sight of other important health care issues.

In March 2020, the World Health Organization declared the coronavirus disease 2019 (COVID-19) to be a pandemic, stating that those with underlying health conditions are most susceptible, including motor neuron disease (MND). To examine the effect the COVID-19 pandemic had on deaths from MND in the United States. Death certificate data for all MND deaths aged 20 years and older were analyzed from 2017 to 2019 (pre-COVID), then expanded to include 2020 and 2021 (COVID) deaths to evaluate if COVID-19 impacted MND deaths. The average number of MND deaths documented during the COVID-19 years was 8009, up from 7485 MND deaths pre-COVID. The age-adjusted mortality rate among the non-Hispanic population increased during COVID to 2.78 per 100,000 persons (95% CI = 2.73–2.82) from 1.81 (95% CI = 1.78–1.84). The Hispanic population also saw an increase in mortality rate during COVID (1.61, 95% CI = 1.51–1.71) compared with pre-COVID (1.10, 95% CI = 1.03–1.17). Decedent’s home as a place of death also saw a mortality rate increase during COVID (1.51, 95% CI = 1.48–1.54) compared with pre-COVID (1.30, 95% CI = 1.27–1.32). For the Hispanic population, the rate peaked at 80–84 years pre-COVID, but for the COVID years, the rate peaked earlier, at 75–79 years. The total number of MND deaths was greater during COVID than in the preceding years. The analysis suggests there might have been a consequence of circumstances surrounding the global pandemic and the associated restrictions.

Note: DPH is updating and streamlining the COVID-19 cases, deaths, and testing data. As of 6/27/2022, the data will be published in four tables instead of twelve.

The COVID-19 Cases, Deaths, and Tests by Day dataset contains cases and test data by date of sample submission. The death data are by date of death. This dataset is updated daily and contains information back to the beginning of the pandemic. The data can be found at https://data.ct.gov/Health-and-Human-Services/COVID-19-Cases-Deaths-and-Tests-by-Day/g9vi-2ahj.

The COVID-19 State Metrics dataset contains over 93 columns of data. This dataset is updated daily and currently contains information starting June 21, 2022 to the present. The data can be found at https://data.ct.gov/Health-and-Human-Services/COVID-19-State-Level-Data/qmgw-5kp6 .

The COVID-19 County Metrics dataset contains 25 columns of data. This dataset is updated daily and currently contains information starting June 16, 2022 to the present. The data can be found at https://data.ct.gov/Health-and-Human-Services/COVID-19-County-Level-Data/ujiq-dy22 .

The COVID-19 Town Metrics dataset contains 16 columns of data. This dataset is updated daily and currently contains information starting June 16, 2022 to the present. The data can be found at https://data.ct.gov/Health-and-Human-Services/COVID-19-Town-Level-Data/icxw-cada . To protect confidentiality, if a town has fewer than 5 cases or positive NAAT tests over the past 7 days, those data will be suppressed.

Count of COVID-19-associated deaths by date of death. Deaths reported to either the OCME or DPH are included in the COVID-19 data. COVID-19-associated deaths include persons who tested positive for COVID-19 around the time of death and persons who were not tested for COVID-19 whose death certificate lists COVID-19 disease as a cause of death or a significant condition contributing to death.

Data on Connecticut deaths were obtained from the Connecticut Deaths Registry maintained by the DPH Office of Vital Records. Cause of death was determined by a death certifier (e.g., physician, APRN, medical examiner) using their best clinical judgment. Additionally, all COVID-19 deaths, including suspected or related, are required to be reported to OCME. On April 4, 2020, CT DPH and OCME released a joint memo to providers and facilities within Connecticut providing guidelines for certifying deaths due to COVID-19 that were consistent with the CDC’s guidelines and a reminder of the required reporting to OCME.25,26 As of July 1, 2021, OCME had reviewed every case reported and performed additional investigation on about one-third of reported deaths to better ascertain if COVID-19 did or did not cause or contribute to the death. Some of these investigations resulted in the OCME performing postmortem swabs for PCR testing on individuals whose deaths were suspected to be due to COVID-19, but antemortem diagnosis was unable to be made.31 The OCME issued or re-issued about 10% of COVID-19 death certificates and, when appropriate, removed COVID-19 from the death certificate. For standardization and tabulation of mortality statistics, written cause of death statements made by the certifiers on death certificates are sent to the National Center for Health Statistics (NCHS) at the CDC which assigns cause of death codes according to the International Causes of Disease 10th Revision (ICD-10) classification system.25,26 COVID-19 deaths in this report are defined as those for which the death certificate has an ICD-10 code of U07.1 as either a primary (underlying) or a contributing cause of death. More information on COVID-19 mortality can be found at the following link: https://portal.ct.gov/DPH/Health-Information-Systems--Reporting/Mortality/Mortality-Statistics

Note the counts in this dataset may vary from the death counts in the other COVID-19-related datasets published on data.ct.gov, where deaths are counted on the date reported rather than the date of death.

Starting in July 2020, this dataset will be updated every weekday. Data are subject to future revision as reporting changes.

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Updated (Bivalent) Booster Status. Click 'More' for important dataset description and footnotes

Webpage: https://covid.cdc.gov/covid-data-tracker/#rates-by-vaccine-status

Dataset and data visualization details:

These data were posted and archived on May 30, 2023 and reflect cases among persons with a positive specimen collection date through April 22, 2023, and deaths among persons with a positive specimen collection date through April 1, 2023. These data will no longer be updated after May 2023.

Vaccination status: A person vaccinated with at least a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. A person vaccinated with a primary series and a monovalent booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably receiving a primary series of an FDA-authorized or approved vaccine and at least one additional dose of any monovalent FDA-authorized or approved COVID-19 vaccine on or after August 13, 2021. (Note: this definition does not distinguish between vaccine recipients who are immunocompromised and are receiving an additional dose versus those who are not immunocompromised and receiving a booster dose.) A person vaccinated with a primary series and an updated (bivalent) booster dose had SARS-CoV-2 RNA or antigen detected in a respiratory specimen collected ≥14 days after verifiably receiving a primary series of an FDA-authorized or approved vaccine and an additional dose of any bivalent FDA-authorized or approved vaccine COVID-19 vaccine on or after September 1, 2022. (Note: Doses with bivalent doses reported as first or second doses are classified as vaccinated with a bivalent booster dose.) People with primary series or a monovalent booster dose were combined in the “vaccinated without an updated booster” category.

Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Per the interim guidance of the Council of State and Territorial Epidemiologists (CSTE), this should include persons whose death certificate lists COVID-19 disease or SARS-CoV-2 as the underlying cause of death or as a significant condition contributing to death. Rates of COVID-19 deaths by vaccination status are primarily reported based on when the patient was tested for COVID-19. In select jurisdictions, deaths are included that are not laboratory confirmed and are reported based on alternative dates (i.e., onset date for most; or date of death or report date, where onset date is unavailable). Deaths usually occur up to 30 days after COVID-19 diagnosis.

Participating jurisdictions: Currently, these 24 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Colorado, District of Columbia, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (NY), North Carolina, Rhode Island, Tennessee, Texas, Utah, and West Virginia; 23 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 48% of the total U.S. population and all ten of the Health and Human Services Regions. This list will be

This mapping tool enables you to see how COVID-19 deaths in your area may relate to factors in the local population, which research has shown are associated with COVID-19 mortality. It maps COVID-19 deaths rates for small areas of London (known as MSOAs) and enables you to compare these to a number of other factors including the Index of Multiple Deprivation, the age and ethnicity of the local population, extent of pre-existing health conditions in the local population, and occupational data. Research has shown that the mortality risk from COVID-19 is higher for people of older age groups, for men, for people with pre-existing health conditions, and for people from BAME backgrounds. London boroughs had some of the highest mortality rates from COVID-19 based on data to April 17th 2020, based on data from the Office for National Statistics (ONS). Analysis from the ONS has also shown how mortality is also related to socio-economic issues such as occupations classified ‘at risk’ and area deprivation. There is much about COVID-19-related mortality that is still not fully understood, including the intersection between the different factors e.g. relationship between BAME groups and occupation. On their own, none of these individual factors correlate strongly with deaths for these small areas. This is most likely because the most relevant factors will vary from area to area. In some cases it may relate to the age of the population, in others it may relate to the prevalence of underlying health conditions, area deprivation or the proportion of the population working in ‘at risk occupations’, and in some cases a combination of these or none of them. Further descriptive analysis of the factors in this tool can be found here: https://data.london.gov.uk/dataset/covid-19--socio-economic-risk-factors-briefing

Effective September 27, 2023, this dataset will no longer be updated. Similar data are accessible from wonder.cdc.gov. This visualization provides weekly data on the number of deaths by jurisdiction of occurrence and cause of death. Counts of deaths in more recent weeks can be compared with counts from earlier years to determine if the number is higher than expected. Selected causes of death are shown, based on analyses of the most prevalent comorbid conditions reported on death certificates where COVID-19 was listed as a cause of death (see https://www.cdc.gov/nchs/nvss/vsrr/covid_weekly/index.htm#Comorbidities). Cause of death counts are based on the underlying cause of death, and presented for Respiratory diseases, Circulatory diseases, Malignant neoplasms, and Alzheimer disease and dementia. Estimated numbers of deaths due to these other causes of death could represent misclassified COVID-19 deaths, or potentially could be indirectly related to COVID-19 (e.g., deaths from other causes occurring in the context of health care shortages or overburdened health care systems). Deaths with an underlying cause of death of COVID-19 are not included in these estimates of deaths due to other causes. Deaths due to external causes (i.e. injuries) or unknown causes are excluded. For more detail, see the Technical Notes.

As of January 6, 2022, an average of 1,192 people per day have died from COVID-19 in the U.S. since the first case was confirmed in the country on January 20th the year before. On an average day, nearly 8,000 people die from all causes in the United States, based on data from 2019. Based on the latest information, roughly one in seven deaths each day were related to COVID-19 between January 2020 and January 2022. However, there were even days when more than every second death in the U.S. was connected to COVID-19. The daily death toll from the seasonal flu, using preliminary maximum estimates from the 2019-2020 influenza season, stood at an average of around 332 people. We have to keep in mind that a comparison of influenza and COVID-19 is somewhat difficult. COVID-19 cases and deaths are counted continuously since the begin of the pandemic, whereas flue counts are seasonal and often less accurate. Furthermore, during the last two years, COVID-19 more or less 'replaced' the flu, with COVID-19 absorbing potential flu cases. Many countries reported a very weak seasonal flu activity during the COVID-19 pandemic. But it has yet to be seen how the two infectious diseases will develop side by side during the winter season 2021/2022 and in the years to come.

Symptoms and self-isolation COVID-19 and influenza share similar symptoms – a cough, runny nose, and tiredness – and telling the difference between the two can be difficult. If you have minor symptoms, there is no need to seek urgent medical care, but it is recommended that you self-isolate, whereas rules vary from country to country. Additionally, rules depend on someone's vaccination status and infection history. However, if you think you have the disease, a diagnostic test can show if you have an active infection.

Scientists alert to coronavirus mutations The genetic material of the novel coronavirus is RNA, not DNA. Other notable human diseases caused by RNA viruses include SARS, Ebola, and influenza. A continual problem that vaccine developers encounter is that viruses can mutate, and a treatment developed against a certain virus type may not work on a mutated form. The seasonal flu vaccine, for example, is different each year because influenza viruses are frequently mutating, and it is critical that those genetic changes continue to be tracked.

The death rate in New York City for adults aged 75 years and older was around 4,135 per 100,000 people as of December 22, 2022. The risk of developing more severe illness from COVID-19 increases with age, and the virus also poses a particular threat to people with underlying health conditions.

What is the death toll in NYC? The first coronavirus-related death in New York City was recorded on March 11, 2020. Since then, the total number of confirmed deaths has reached 37,452 while there have been 2.6 million positive tests for the disease. The number of daily new deaths in New York City has fallen sharply since nearly 600 residents lost their lives on April 7, 2020. A significant number of fatalities across New York State have been linked to long-term care facilities that provide support to vulnerable elderly adults and individuals with physical disabilities.

The impact on the counties of New York State Nearly every county in the state of New York has recorded at least one death due to the coronavirus. Outside of New York City, the counties of Nassau, Suffolk, and Westchester have confirmed over 11,500 deaths between them. When analyzing the ratio of deaths to county population, Rockland had one of the highest COVID-19 death rates in New York State in 2021. The county, which has approximately 325,700 residents, had a death rate of around 29 per 10,000 people in April 2021.

Understanding Global Excess Deaths During the COVID-19 Pandemic: Insights from The Economist Data

The COVID-19 pandemic has left an indelible mark on societies worldwide, not only through its direct impact on health but also through its ripple effects on various aspects of life. As we strive to comprehend the full extent of its toll, one crucial metric that emerges is excess deaths – a measure encompassing not only confirmed COVID-19 fatalities but also those indirectly caused by the pandemic. In this discourse, we delve into the comprehensive dataset provided by The Economist and processed by Our World in Data, shedding light on the central estimates and uncertainty intervals of global excess deaths.

The dataset, meticulously compiled and analyzed by The Economist, serves as a cornerstone for understanding the broader implications of the pandemic beyond official death counts. This invaluable resource, available for public scrutiny and further research, offers insights into the nuanced dynamics of excess mortality across different regions and timeframes.

Central to our exploration are the central estimates provided by The Economist, representing the best approximation of excess deaths attributable to the pandemic. These figures, derived through rigorous statistical methodologies, provide a foundational understanding of the pandemic's impact on mortality rates globally. By accounting for excess deaths beyond what would typically be expected, these estimates paint a clearer picture of the true toll of COVID-19.

Accompanying these central estimates are uncertainty intervals, reflecting the range within which the true value of excess deaths is likely to fall. As with any statistical analysis, uncertainties abound, stemming from various factors such as data collection methods, reporting inconsistencies, and the inherent complexity of modeling excess mortality. Acknowledging these uncertainties is paramount in interpreting the data accurately and avoiding overgeneralizations or misinterpretations.

Delving deeper into the dataset, it becomes evident that the magnitude of excess deaths varies significantly across different regions and time periods. Factors such as healthcare infrastructure, socio-economic disparities, and the stringency of public health measures exert profound influences on mortality outcomes. By dissecting these variations, policymakers and public health experts can glean invaluable insights to inform targeted interventions and mitigate future crises.

Moreover, the dataset underscores the interconnectedness of global health, highlighting how the impact of the pandemic transcends geographical boundaries. As nations grapple with containing the spread of the virus within their borders, the ripple effects of excess mortality reverberate across the international community. This interconnectedness underscores the importance of collective action and solidarity in addressing not only the immediate challenges posed by the pandemic but also the long-term ramifications on global health security.

It is essential to note that behind every data point lies a human story – a life lost, a family shattered, a community grieving. Amidst the statistical analyses and epidemiological models, it is imperative not to lose sight of the human dimension of the pandemic. Each excess death represents more than just a number; it embodies a profound loss and underscores the urgency of concerted efforts to prevent further tragedies.

In conclusion, the dataset provided by The Economist and processed by Our World in Data offers a comprehensive lens through which to understand the complexities of excess mortality during the COVID-19 pandemic. By interrogating the central estimates and uncertainty intervals, we gain critical insights into the multifaceted dimensions of the pandemic's impact on global mortality rates. Moving forward, leveraging these insights to inform evidence-based policies and interventions is paramount in mitigating the ongoing crisis and building resilient health systems for the future.

COVID-19 mortality rates increase rapidly with age, are higher among men than women, and vary across racial/ethnic groups, but this is also true for other natural causes of death. Prior research on COVID-19 mortality rates and racial/ethnic disparities in those rates has not considered to what extent disparities reflect COVID-19-specific factors, versus preexisting health differences. This study examines both questions. We study the COVID-19-related increase in mortality risk and racial/ethnic disparities in COVID-19 mortality, and how both vary with age, gender, and time period. We use a novel measure validated in prior work, the COVID Excess Mortality Percentage (CEMP), defined as the COVID-19 mortality rate (Covid-MR), divided by the non-COVID natural mortality rate during the same time period (non-Covid NMR), converted to a percentage. The CEMP denominator uses Non-COVID NMR to adjust COVID-19 mortality risk for underlying population health. The CEMP measure generates insights which differ from those using two common measures–the COVID-MR and the all-cause excess mortality rate. By studying both CEMP and COVID-MRMR, we can separate the effects of background health from Covid-specific factors affecting COVID-19 mortality. We study how CEMP and COVID-MR vary by age, gender, race/ethnicity, and time period, using data on all adult decedents from natural causes in Indiana and Wisconsin over April 2020-June 2022 and Illinois over April 2020-December 2021. CEMP levels for racial and ethnic minority groups can be very high relative to White levels, especially for Hispanics in 2020 and the first-half of 2021. For example, during 2020, CEMP for Hispanics aged 18–59 was 68.9% versus 7.2% for non-Hispanic Whites; a ratio of 9.57:1. CEMP disparities are substantial but less extreme for other demographic groups. Disparities were generally lower after age 60 and declined over our sample period. Differences in socio-economic status and education explain only a small part of these disparities.

Detroit-specific ZIP code populations, along with their cumulative COVID case counts, deaths, and rates. Data provided by Detroit Health Department. The public-facing COVID Cases Dashboard is hosted at: detroitmi.gov/healthUPDATE* July 29 2021:The underlying calculation for disease date was updated to allow for individuals to appear on the curve in multiple locations if they experienced more than one case of COVID-19 that was at least 90 days apart.Geospatial information analysis was also improved and additional criterial for address clean up were implemented, which leads to more accurate case counts within Zip Codes. Some unverified addresses that may have appeared in previous Zip Code counts are now excluded.This change discourages direct comparison of dashboard visualizations and counts prior to the new calculation, and non-significant shifts in numbers will be noticed.Case numbers represent Detroit residents only. Some ZIP codes with very low case counts are excluded to protect privacy. Case counts are totals per ZIP code and are not adjusted for population. ZIP code totals are preliminary; addresses are updated as new information becomes available and counts are subject to change. Not all cases have an accurate location; only cases with a known ZIP code are represented. Where a ZIP code is split between cities, only the Detroit portion is shown (48203, 48211, 48212, 48236, 48239). The counts exclude cases among prisoners at the Wayne County Jail and known hospital or laboratory locations.ZIP_Code: The USPS ZIP postal code Clipped_ZIP_Population: The 2010 population of the ZIP code, clipped to include Detroit City residents only.ZIP_Case_Count: The current cumulative count of Confirmed COVID cases within the ZIP code, since the beginning of the pandemic. (Have a "Confimed" case status in MDSS)ZIP_Death_Count: The current cumulative count of Confirmed COVID cases within the ZIP code, since the beginning of the pandemic. (Have a "Confimed" case status in MDSS and are deceased)ZIP_Case_Rate: Rate of confirmed cases per 100 thousand residents in the ZIP code. For each zip, the rate was calculated by (C/P)*100000 C = the count of confirmed (MDSS case status = Confirmed) cases with a resident address in the ZIP code P = the population count of the ZIP codeZIP_Death_Rate: Rate of confirmed cases that were marked deceased, per 100 thousand residents in the ZIP code. For each zip, the rate was calculated by (D/P)*100000 D = the count of confirmed (MDSS case status = Confirmed) cases marked as deceased, with a resident address in the ZIP P = the population count of the ZIP code

Age-standardised mortality rates for deaths involving coronavirus (COVID-19), non-COVID-19 deaths and all deaths by vaccination status, broken down by age group.

As of May 2, 2023, there were roughly 687 million global cases of COVID-19. Around 660 million people had recovered from the disease, while there had been almost 6.87 million deaths. The United States, India, and Brazil have been among the countries hardest hit by the pandemic.

The various types of human coronavirus The SARS-CoV-2 virus is the seventh known coronavirus to infect humans. Its emergence makes it the third in recent years to cause widespread infectious disease following the viruses responsible for SARS and MERS. A continual problem is that viruses naturally mutate as they attempt to survive. Notable new variants of SARS-CoV-2 were first identified in the UK, South Africa, and Brazil. Variants are of particular interest because they are associated with increased transmission.

Vaccination campaigns Common human coronaviruses typically cause mild symptoms such as a cough or a cold, but the novel coronavirus SARS-CoV-2 has led to more severe respiratory illnesses and deaths worldwide. Several COVID-19 vaccines have now been approved and are being used around the world.

BackgroundTuberculosis (TB) is still one of the most important causes of death worldwide. The lack of timely attention on TB diagnosis and treatment during the coronavirus disease 2019 (COVID-19) pandemic is a potential threat to health issues and may have severe consequences for patients and health systems. There is not much information on the management of TB during this period. Here, we reviewed the current literature to evaluate the rate of Mycobacterium tuberculosis and severe acute respiratory syndrome coronavirus 2 coinfections and interactions between these infectious agents.MethodsSeveral databases, including Web of Science, Scopus, and MEDLINE (via PubMed), were searched for original articles addressing TB and COVID-19 diseases published from December 2019 to April 2021.ResultsOf 3,879 articles, 57 articles were included in this study, and among 106,033 patients affected by COVID-19, 891 also had TB. Overall, investigators found a consistent increase in C-reactive protein, D-dimer (especially in patients with severe clinical manifestation), erythrocyte sedimentation rate, lactate dehydrogenase, alanine aminotransferase, and a reduction of lymphocytes. The respiratory symptoms of TB/COVID-19 patients were similar to those of TB patients, but the risk of developing pulmonary TB increased in COVID-19 patients. Also, the mortality rate in TB/COVID-19 patients was higher than that in patients affected only by COVID-19 or TB.ConclusionSome reports indicated worsening respiratory symptoms and even activation of latent TB after COVID-19 or vice versa. It seems that both active and previously treated TB constituted a risk factor for COVID-19 in terms of severity and mortality, regardless of other underlying diseases and patient status. Health systems should not neglect TB during this era of the ongoing COVID-19 pandemic by setting up appropriate diagnostic and clinical management algorithms.